Headache News and Research

Latest Headache News and Research

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

House Judiciary Committee calls for another hearing to assess football-related brain injuries

Chairman of the House Judiciary Committee John Conyers has called for another hearing on brain injuries in football to be held on Monday, January 4.

4 Jan 2010

ESS improves quality of life in CRS patients

Upwards of 76 percent of patients with chronic rhinosinusitis (CRS) experienced significant quality of life (QOL) improvements after undergoing endoscopic sinus surgery (ESS), according to new research in the January 2010 issue of Otolaryngology - Head and Neck Surgery.

3 Jan 2010

PHT comments on FDA's PRO Final Guidance

PHT Corporation, the leading provider of ePRO (electronic patient reported outcome) solutions used in more than 400 clinical trials worldwide, commented on the FDA’s recent release of a final guidance almost four years following a Draft Guidance on the topic. The Final Guidance is entitled: Guidance for Industry, Patient-Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims.

24 Dec 2009

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Senate rejects mass importation of medicine from Canada

In the midst of President Obama's push for health care reform, the Senate rejected a plan to allow American pharmacies and drug wholesalers to import federally approved drugs from abroad. That vote has proved to be a headache for customer service staff at companies like Canadameds.com (http://www.Canadameds.com), which sells low-cost prescription drugs directly to American consumers.

24 Dec 2009

Fluzone High-Dose inactivated influenza virus vaccine receives FDA approval

The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.

24 Dec 2009

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.

22 Dec 2009

FDA extends action date for its review of Cephalon's sNDA for NUVIGIL Tablets

Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].

22 Dec 2009

Probiotic hangover cure

The holiday season can be a real headache for employers as absenteeism increases as the party season approaches. Everyone looks forward to the parties, social gatherings and family meals as opportunities to abandon self-discipline and enjoy all that the festive season has to offer. Even the most disciplined can end up feeling “under the weather” the morning after and this often leads to a sick day.

21 Dec 2009

Headache on rare occasions can be a warning sign of potentially serious disorder

Headaches are extremely common. Almost everyone has experienced a severe headache at least once in his or her lifetime. In most cases, headaches are minor nuisances that resolve within a short time. However, a headache can on rare occasions be the warning sign of a potentially serious disorder that requires immediate medical attention.

19 Dec 2009

Diabetes patients at higher risk from glaucoma

An estimated 3 million Americans have glaucoma, which can stealthily cause vision loss even before people realize they have the disease. People with diabetes face special risks from glaucoma. This January during Glaucoma Awareness Month, through its EyeSmart™ campaign, the American Academy of Ophthalmology in partnership with the American Glaucoma Society and the Glaucoma Research Foundation, remind Americans that knowing your glaucoma risks can save your sight and that people with diabetes need to be extra-vigilant.

19 Dec 2009

Bourbon causes a worse hangover than vodka

Many alcoholic beverages contain byproducts of the materials used in the fermenting process. These byproducts are called "congeners," complex organic molecules with toxic effects including acetone, acetaldehyde, fusel oil, tannins, and furfural. Bourbon has 37 times the amount of congeners that vodka has. A new study has found that while drinking a lot of bourbon can cause a worse hangover than drinking a lot of vodka, impairment in people's next-day task performance is about the same for both beverages.

19 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

Majority of Canadians confuse sinusitis with H1N1 symptoms

It's winter, that great Canadian season of snow, ice, grey skies...and colds and the flu. In a year when H1N1 is high on everyone's radar, it is more important than ever for Canadians to know what their symptoms mean and when they should see their doctor.

17 Dec 2009

UC San Diego Medical Center performs complex surgery on brain lesion

Over three decades, a world-recognized medical team at UC San Diego Medical Center has spurred the evolution of a complex surgery to destroy dangerous clusters of arteries and veins in the brain. Integrating innovative approaches in radiology, anesthesia, and surgery, the team has perfected a method to systematically starve these abnormal brain lesions, artery by artery, vein by vein.

17 Dec 2009

On and off Capitol Hill, politicians are taking positions on health bill

Roll Call: "Sen. Susan Collins (R-Maine) on Tuesday said she does not believe that the Senate Democratic health care reform bill will garner her vote, despite significant changes that are likely to be made to rid the bill of a public insurance option and an expansion of Medicare. Democrats have regarded Collins, along with fellow moderate Maine Republican Sen. Olympia Snowe, as potentially persuadable on the bill.

16 Dec 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®

16 Dec 2009

NovaDel receives Issue Notification from USPTO for oral spray

NovaDel Pharma Inc., today announced that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a new U.S. Patent, No. 7632517, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaDel’s oral spray technology.

16 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009